The clinical research on the efficacy of Tanreiqing injection combined with routine western medicine in treating chronic obstructive pulmonary disease at acute and aggravating period with syndrome of phlegm-heat obstructing lung
10.3760/cma.j.issn.1673-4246.2020.02.004
- VernacularTitle: 痰热清注射液结合西医常规疗法治疗慢性阻塞性肺疾病急性加重痰热壅肺证临床研究
- Author:
Fanping CHEN
1
;
Yumei YIN
;
Bolan LIN
Author Information
1. Respiratory Department, Shijiazhuang Hospital of Traditional Chinese Medicine, Shijiazhuang 050011, China
- Publication Type:Clinical Trail
- Keywords:
Pulmonary disease, chronic obstructive;
Acute disease;
Phlegm heat obstructing Lung;
Tan Re Qing Zhu She Ye;
Integrated Chinese traditional and western medicine therapy;
Drug-related side effects and adverse reactions
- From:
International Journal of Traditional Chinese Medicine
2020;42(2):115-119
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate effect of Tanreqing injection combined conventional western medicine therapy on acute exacerbation of chronic obstructive pulmonary disease (AECOPD) of Phlegm heat obstructing Lung.
Methods:A total of 112 patients with AECOPD were randomly divided into two groups with digital table method from February 2015 to February 2018, 56 cases in each group. The control group was treated byconventional western medicine therapy, and treatment group was treated by Tanreqing injection based on control group. Both groups' treatment lasted for 2 weeks. The modified version of British Medical Reseach Council respiratory questionnaire (mMRC) was used for severity evaluation in breath difficulty. The COPD assessment test (CAT) was used for the assessment of symptoms, activity ability, psychological, social impact and sleep. The FEV1% and FEV1/FVC were recorded. The SaO2, PaO2 and PaCO2 were recorded. The phlegm heat obstructing lung symptom scores were detected. The adverse reactions were recorded.
Results:The total effective rate of treatment group was 94.4% (51/54), and the control group was 77.3% (41/53). There was statistically significant difference between two groups (χ2=5.138, P=0.023). After treatment, the mMRC and CAT scores in the treatment group were significantly lower than those in the control group (t value were 17.233, 17.111, respectively, all Ps<0.01); the cough, wheezing, shortness of breath, fever, dry mouth, constipation scores were significantly lower than the control group (t value were 27.717, 29.387, 27.227, 30.268, 28.430, 29.738, respectively, all Ps<0.01). After treatment, the FEV1% (52.34% ± 5.79% vs. 46.98% ± 5.72%, t=4.817), FEV1/FVC (61.36 ± 6.52 vs. 56.93 ± 5.94, t=3.675) in the treatment group were significantly higher than the control group (P<0.01); SaO2 (90.11% ± 9.53% vs. 83.56% ± 8.84%, t=3.684); the PaO2 (91.22 ± 9.79 mmHg vs. 85.18 ± 8.80 mmHg, t=3.354) significantly higher than the control group (P<0.01), and PaCO2 (44.75 ± 4.94 mmHg vs. 51.05 ± 5.46 mmHg, t=6.261) significantly lower than the control group (P<0.01). The incidence of adverse reactions in the treatment group was 11.1% (6/54), and the control group was 7.5% (4/53). There was no statistically significant difference between two groups (χ2=0.091, P=0.763).
Conclusions:Tanreiqing injection combined with conventional western medicine therapy can take effectsimprove levels of SaO2 and PaO2, reduce PaCO2 level of the AECOPD patients.
